Project: Development of CMTM6 inhibitors: Modulation of PDL1 for cancer treatment

Acronym	Immune-NOVA (Reference Number: 12710)
Duration	01/03/2019 - 03/03/2022
Project Topic	Immune-NOVA aims to establish preclinical proof-of-concept in in vivo oncology models and in relevant patient-derived in vitro cell models for a novel immune checkpoint inhibitor targeting CMTM6. This inhibitor blocks a known immune checkpoint axis, PD-1/PD-L1, by decreasing cell surface expression of PD-L1, and so potentiates anti-tumour immunity. This novel inhibitor can be used to treat advanced forms of cancer, such as lung cancer, skin cancer (melanoma) and kidney cancer.
Network	Eurostars 2
Call	Eurostars Cut–off 10

Project partner

Number	Name	Role	Country
1	Scenic Biotech B.V.	Coordinator	Netherlands
2	InSphero AG	Partner	Switzerland
3	Adlego Biomedical AB	Partner	Sweden